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Introduction: Estrogen deprivation using aromatase inhibitors (AIs) is currently the standard of care for postmenopausal
women with hormone receptor-positive breast cancer. Unfortunately, the majority of patients treated with AIs eventually
develop resistance, inevitably resulting in patient relapse and, ultimately, death. The mechanism by which resistance
occurs is still not completely known, however, recent studies suggest that impaired/defective interferon signaling
might play a role. In the present study, we assessed the functional role of IFITM1 and PLSCR1; two well-known interferon
response genes in AI resistance.
Methods: Real-time PCR and Western blot analyses were used to assess mRNA and protein levels of IFITM1, PLSCR1,
STAT1, STAT2, and IRF-7 in AI-resistant MCF-7:5C breast cancer cells and AI-sensitive MCF-7 and T47D cells.
Immunohistochemistry (IHC) staining was performed on tissue microarrays consisting of normal breast tissues, primary
breast tumors, and AI-resistant recurrence tumors. Enzyme-linked immunosorbent assay was used to quantitate
intracellular IFNα level. Neutralizing antibody was used to block type 1 interferon receptor IFNAR1 signaling. Small
interference RNA (siRNA) was used to knockdown IFITM1, PLSCR1, STAT1, STAT2, IRF-7, and IFNα expression.
Results: We found that IFITM1 and PLSCR1 were constitutively overexpressed in AI-resistant MCF-7:5C breast
cancer cells and AI-resistant tumors and that siRNA knockdown of IFITM1 significantly inhibited the ability of
the resistant cells to proliferate, migrate, and invade. Interestingly, suppression of IFITM1 significantly enhanced
estradiol-induced cell death in AI-resistant MCF-7:5C cells and markedly increased expression of p21, Bax, and
Noxa in these cells. Significantly elevated level of IFNα was detected in AI-resistant MCF-7:5C cells compared to
parental MCF-7 cells and suppression of IFNα dramatically reduced IFITM1, PLSCR1, p-STAT1, and p-STAT2 expression in
the resistant cells. Lastly, neutralizing antibody against IFNAR1/2 and knockdown of STAT1/STAT2 completely suppressed
IFITM1, PLSCR1, p-STAT1, and p-STAT2 expression in the resistant cells, thus confirming the involvement of the canonical
IFNα signaling pathway in driving the overexpression of IFITM1 and other interferon-stimulated genes (ISGs) in
the resistant cells.
Conclusion: Overall, these results demonstrate that constitutive overexpression of ISGs enhances the progression
of AI-resistant breast cancer and that suppression of IFITM1 and other ISGs sensitizes AI-resistant cells to
estrogen-induced cell death.* Correspondence: jlewis-wambi@kumc.edu
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Aromatase inhibitors (AIs) are more effective than the
antiestrogen tamoxifen at inhibiting the growth and pro-
liferation of estrogen receptor (ER)-positive breast can-
cer [1] and these agents are now front-line treatments
for postmenopausal women with hormone receptor-
positive breast cancer in both the adjuvant and meta-
static setting [2,3]. AIs suppress estrogen synthesis in
postmenopausal women by inhibiting the aromatase en-
zyme, which catalyzes the conversion of androgens to
estrogens [1,2,4,5]. Unfortunately, the majority of pa-
tients treated with AIs eventually develop resistance to
these drugs [6] and when resistance occurs it is unclear
which endocrine therapy is the most appropriate. Re-
cently, there has been increasing clinical evidence to
suggest that 17β-estradiol (E2) would be an appropriate
and effective treatment option for postmenopausal pa-
tients with AI-resistant breast cancer [7,8]. Indeed, pre-
clinical studies from our laboratory [9-12] and other
investigators [13,14]) have previously shown that long
term estrogen deprivation of ER-positive MCF-7 breast
cancer cells causes them to lose their dependency on es-
tradiol for proliferation, which recapitulates acquired re-
sistance to aromatase inhibitors in postmenopausal
women, and that these AI-resistant breast cancer cells
paradoxically undergo apoptosis in the presence of estra-
diol [10-12,15,16]. The ability of estradiol to induce
apoptosis in AI-resistant breast cancer cells was previ-
ously shown to be mediated, in part, by the mitochon-
dria death pathway [11]; however, more recent findings
suggest that dysregulation of the interferon signaling
pathway might also play a role in estradiol-induced cell
death [17].
Interferons (IFNs) are a class of glycoproteins known
as cytokines that are produced by immune cells of most
vertebrates and are secreted in response to viral infec-
tions, tumors, and other pathogenic microbial agents
[18]. IFNs diffuse to the surrounding cells and bind to
high affinity cell surface type I (IFNα/β) and type II
(IFNγ) receptors (IFNAR1/2), leading to phosphorylation
and activation of JAK1, JAK2 and Tyk2. Activated
JAKs phosphorylate and activate STAT1 and STAT2,
resulting in the formation of STAT1-STAT1 homodi-
mers and STAT1-STAT2 heterodimers. The dimers are
transported to the nucleus by importins and bind to
IFN-stimulated response elements (ISREs) to activate
the transcription of interferon-stimulated genes (ISGs),
such as IFITM1, PLSCR1, STAT1, IFI27 and IFIT1 [18-20].
The interferon signaling pathway plays an important role
in the proper functioning of the immune system [21] and
there is strong evidence that its dysregulation, resulting in
constitutive overexpression of ISGs contributes to tumori-
genesis [22] and possibly drug resistance [23]. Indeed, our
laboratory has previously shown through microarrayanalysis that immune response and interferon signaling
pathways are significantly altered in AI-resistant breast
cancer cells and that several interferon response genes in-
cluding IFITM1, PLSCR1 and STAT1 are constitutively
overexpressed in AI-resistant breast cancer cells [17,24]. At
present, however, the functional significance of the inter-
feron signaling pathway in AI-resistance or its potential in-
volvement in estradiol-induced cell death is not known.
Interferon-inducible transmembrane protein 1 (IFITM1)
is a cell surface 17 kDa membrane protein that is a mem-
ber of the IFN-inducible transmembrane protein family
that includes IFITM2, IFITM3 and IFITM5 [25,26]. The
IFITM1 gene is located on the short arm of chromosome
11 (11p15.5) and is 3,956 bases in length. IFITM1 expres-
sion is highly induced by IFNα and IFNβ to a lesser extent,
IFNγ [27]. IFITM1 was initially identified as Leu13, a
leukocyte antigen that is part of a membrane complex in-
volved in the transduction of antiproliferative and homoty-
pic adhesion signals in lymphocytes [28,29]. IFITM1 is also
known to play a critical role in blocking early stages of viral
replication and it potently restricts entry and infections by
a number of highly pathogenic viruses, including HIV-1,
filovirus, and SARS coronavirus [30]. More recently, there
has been increasing evidence to suggest that high expres-
sion of IFITM1 plays a role in the progression of several
cancers including head and neck cancer, serous ovarian
cancer, gastric cancer and colorectal cancer [29,31-33].
However, its role in breast cancer or endocrine resistance
is not known.
Phospholipid scramblase 1 (PLSCR1) is a 35 kDa
multiply palmitoylated protein that is localized in the
cell membrane and is responsible for mediating the
translocation of negatively-charged phospholipids from
the inner-leaflet of the plasma membrane to the outer-
leaflet during cellular injury and apoptosis [34,35].
PLSCR1 is highly induced by type 1 IFNs and it plays an
antagonistic role in leukemia [36] and ovarian cancer [37];
however, its role in breast cancer is unknown.
In the present study, we investigated the functional
role of IFITM1 and PLSCR1 in AI-resistant breast can-
cer. We found that IFITM1 and PLSCR1 were constitu-
tively overexpressed in AI-resistant MCF-7:5C breast
cancer cells and AI-resistant tumors and that knock-
down of IFITM1 significantly reduced their ability to
proliferate, invade, and migrate. Most interestingly, we
found that suppression of IFITM1 sensitized AI-resistant
MCF-7:5C cells to estradiol-induced cell death. Suppres-
sion of IFNα level via siRNA knockdown of IRF-7 con-
firmed that the constitutive overexpression of IFITM1
and PLSCR1 in the resistant cells was driven by in-
creased intracellular levels of IFNα. Further analysis
using neutralizing antibody against IFNAR and siRNA
knockdown of STAT1 and STAT2 revealed complete
suppression of IFITM1, PLSCR1, p-STAT1 and p-STAT2
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canonical IFNα signaling in the regulation of IFITM1
and other ISGs in the resistant cells.
Methods
Reagents
RPMI 1640 and fetal bovine serum (FBS) were obtained
from Invitrogen Inc. (Grand Island, NY, USA). The
antibiotic/antimycotic solution (containing 10,000 U/mL
penicillin and 10 mg/mL streptomycin, 25 μg/mL of
Fungizone®), NEAA (MEM Non-Essential Amino Acids),
L-glutamine, and TrypLE (containing trypsin and ethylene-
diaminetetraacetic acid (EDTA)) were obtained from Invi-
trogen. Insulin (bovine pancrease), human recombinant
interferon-alpha (IFNα) and 17β-estradiol (E2) were ob-
tained from Sigma-Aldrich Co. (St. Louis, MO, USA). E2
was dissolved in ethanol at a stock concentration of 1 μM
(10−6 M) and stored at −20°C. Anti-PLSCR1, anti-IFITM1,
anti-IRF-7, anti-STAT1, anti-Bax, anti-Noxa, anti-PUMA,
anti-p53, anti-p21, anti-Lamin B, anti-IFNAR (α − IFNAR),
anti-p-STAT2 (Tyr690) and anti-ERα antibodies were pur-
chased from Santa Cruz Technology Inc. (Santa Cruz, CA,
USA); anti- poly ADP ribose polymerase (PARP) and anti-
p-STAT1 (Y701) were purchased from Cell Signaling
Technology (Beverly, MA, USA), and anti-β-actin was pur-
chased from Sigma-Aldrich. PLSCR1 monoclonal antibody
4D2 was a kind gift from Dr. Peter Sims (University of
Rochester, NY, USA).
Cell lines and culture conditions
The ER-positive hormone-dependent human breast can-
cer cell lines, MCF-7 and T47D, were originally obtained
from the American Type Culture Collection (Manassas,
VA, USA) and were maintained in full serum medium
composed of RPMI-1640 medium, 10% FBS, 2 mM
glutamine, penicillin at 100 U/mL, streptomycin at
100 μg/mL, 1× NEAA (Invitrogen) and bovine insulin at
6 ng/mL (Sigma-Aldrich). The long term estrogen de-
prived human breast cancer cell line MCF-7:5C [9,12]
was cloned from parental MCF-7 cells following long
term (>12 months) culture in estrogen-free medium
composed of phenol red-free RPMI-1640, 10% FBS treated
three times with dextran-coated charcoal (SFS), 2 mM glu-
tamine, bovine insulin at 6 ng/mL, penicillin at 100 U/mL,
streptomycin at 100 μg/mL, and 1× NEAA. The MCF-
7:5C cell line was used as a model of AI resistance because
it proliferates despite being deprived of estrogen [9,12].
Cells were cultured at 37°C under 5% CO2 and were sub-
cultured every three to four days.
MTT assay
For determining cell viability, the 3-(4,5-dimethylthiazol-
2-Yl)-2,5-diphenyltetrazolium bromide (MTT) assay was
used. MCF-7 and MCF-7:5C cells were seeded onto24-well plates at a density of 5 × 104 cells per well in
culture media and incubated until about 60% to 70% con-
fluency, before the start of experimental treatments. The
stock solution of E2 was diluted in the culture medium
before addition to each well at desired final concentra-
tions, and the treatments usually lasted 24 hours. Follow-
ing the treatments as indicated, 50 μl of MTT solution
(at 5 mg/mL) was added to each well at a final concentra-
tion of 500 μg/mL, and the mixture was further incu-
bated for four hours at 37°C. An aliquot (500 μl) of the
solubilizing solution (dimethyl sulfoxide (DMSO):ethanol,
1:1, v:v) was then added to each well, and the absorbance
was read with a UV max microplate reader (Molecular
Device, Palo Alto, CA, USA) at 560 nm. The relative cell
density was expressed as a percentage of the control that
was not treated with E2.
Western blotting
For Western blotting, cells were washed first and then
suspended in 100 μL lysis buffer (RIPA buffer, 150 mM
NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycho-
late, 0.1% SDS, 50 mM Tris, pH 8.0, protease inhibitor
cocktail, and phosphatase inhibitor). The amount of pro-
teins was determined using the Bio-Rad protein assay
(Bio-Rad, Hercules, CA, USA). An equal amount of pro-
teins was loaded in each lane. The proteins were separated
by 4% to 12% SDS–polyacrylamide gel electrophoresis
(SDS–PAGE) and electrically transferred to a polyvinyli-
dene difluoride membrane (Bio-Rad). After blocking the
membrane using 5% non-fat milk, target proteins were de-
tected using specific antibodies. Thereafter, horseradish
peroxidase (HRP)-conjugated anti-rabbit (or anti-mouse)
immunoglobulin G (IgG) was applied as the secondary
antibody and the positive bands were detected using
Amersham ECL Plus Western blotting detection reagents
(GE Health Care, Piscataway, NJ, USA).
Nuclear and cytoplasmic fractionation
For protein localization, the nuclear and cytosolic frac-
tions were prepared using the cytosolic/nuclear fraction-
ation kit obtained from Biovision Inc. (Mountain View,
CA, USA), by following the instructions of the manufac-
turer. Briefly, cells were suspended in hypotonic buffer
and lysed with the proprietary detergent from the kit.
Samples were spun at 800 × g for 10 minutes at 4°C. The
supernatant was collected, spun five minutes at 16,000 × g
to remove any remaining nuclei, and then transferred to a
new microtube (cytosolic protein fraction). The original
pellet was resuspended in the nuclear extraction buffer and
then incubated on ice for 40 minutes with occasional vor-
texing. After salt extraction, the nuclear pellet was centri-
fuged at 16,000 × g for 10 minutes, and the supernatant
was saved as the nuclear extract. Extracts were stored in
aliquots in −80°C until use.
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An annexin V–fluorescein isothiocyanate (FITC)-labeled
Apoptosis Detection Kit I (Pharmingen, San Diego, CA,
USA) was used to detect and quantify apoptosis by flow
cytometry according to the manufacturer’s instructions.
In brief, MCF-7:5C cells (1 × 106 cells/mL) were seeded
in 100-mm dishes and cultured overnight in estrogen-
free RPMI 1640 medium containing 10% SFS. The next
day, cells were treated with <0.1% ethanol vehicle (control)
and E2 (1 nM) for 96 hours and then harvested in cold
PBS (Invitrogen) and collected by centrifugation for 10 mi-
nutes at 500 × g. Cells were then resuspended at a density
of 1 × 106 cells/mL in 1 × binding buffer (HEPES buffer,
10 mM, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2
and 1.8 mM CaCl2) and stained simultaneously with
FITC-labeled annexin V (25 ng/mL; green fluorescence)
and propidium iodide (PI) (50 ng/mL). PI was provided as
a 50 μg/mL stock (Pharmingen) and was used as a cell via-
bility marker. Cells were analyzed using the BD LSR II flow
cytometer (BD Bioscience, San Jose, CA, USA), and the
data were analyzed with CellQuest software.
Immunofluorescence microscopy
Cells grown on glass coverslips were washed in PBS and
fixed with 4% formaldehyde in PBS for 30 minutes. After
permeabilization by 0.2% Triton X-100 in PBS for 5 mi-
nutes, cells were incubated with 0.1 mg/mL RNAse in
2% whole goat serum/PBS for 30 minutes at 37°C,
followed by incubation with PLSCR1 (4D2) or IFITM1
antibody, 5 μg/mL in 2% goat serum/PBS (Jackson
Immuno Research Labs Inc., West Grove, PA, USA) for
one hour. Cells were stained with FITC-conjugated la-
beled goat anti-mouse IgG, 4 μg/mL in PBS for one
hour, followed by nuclear counterstain with 4′,6-diami-
dino-2-phenylindole (DAPI) 0.1 μg/mL in PBS for 10 mi-
nutes. Coverslips were mounted on glass slides with
Vectashield Mounting medium (Vector Laboratories,
Burlingame, CA, USA), and samples were analyzed on a
Bio-Rad MRC-1024 laser scanning confocal microscope
equipped with a Zeiss X60 objective. Images were col-
lected using Bio-Rad’s Laser Sharp software. Specificity
of staining observed for PLSCR1 mab 4D2 was evaluated
by cell staining with the identical concentration of an
isotype-matched antibody.
Cell cycle analysis
MCF-7:5C cells were transfected with siCon, siPLSCR1
or siIFITM1 for 72 hours and then harvested by trypsi-
nization and washed once with phosphate-buffered sa-
line (PBS, pH 7.4). After centrifugation, cells were
resuspended in 1 mL of 0.9% NaCl, followed by addition
of 2.5 mL of ice-cold 90% ethanol. After incubation at
room temperature for 30 minutes, cells were centrifuged
and the supernatant was removed. Cells were resuspendedin 1 mL PBS containing 50 μg/mL PI and 100 μg/mL ribo-
nuclease A and incubated at 37°C for 30 minutes. Flow cy-
tometric analyses were performed using the BD LSR II
flow cytometer (BD Bioscience, San Jose, CA, USA).
Enzyme-linked immunosorbent assay
Measurement of human interferon-α (IFNα) was con-
ducted by enzyme-linked immunosorbent assay (ELISA)
(PBL Interferon Source, Piscataway, NJ, USA). One mil-
lion MCF-7 or MCF-7:5C cells were seeded in six-well
plates and allowed to acclimatize overnight. They were
then treated with 250 U/mL human recombinant IFNα
for 24 hours. Cells and supernatants were harvested after
24 hours and kept at −80°C until analysis. Protein was
extracted by sonication in RIPA buffer supplemented
with protease and phosphatase inhibitors. Supernatants
and lysates were purified by centrifugation and analyzed
for the presence of IFNα according to the manufacturer’s
instructions.
IFNAR neutralization
In order to achieve neutralization of type 1 interferon,
IFNAR, MCF-7 and MCF-7:5C cells were pretreated
with 5 μg/mL anti-IFNAR1/2/MMHAR2 from Millipore,
Temecula, CA, USA (cat# MAB1155) for four hours and
then treated overnight with 20 U/mL human recombin-
ant IFNα (Sigma) or 1 nM E2 (Sigma) where indicated.
Cells were harvested by cell scraping for Western blot
and by trypsinization for cell viability analysis with try-
pan blue count.
Small interfering RNA transfections
For small interfering RNA (siRNA) knockdown experi-
ments, MCF-7:5C and MCF-7 cells were transiently
transfected with PLSCR1-siRNA (h) (siPLSCR1), IFITM1-
siRNA (h) (siIFITM1), STAT1-siRNA (h) (siSTAT1),
STAT2-siRNA (h) (siSTAT2), IFNα2-siRNA (h) (siIFNα2),
IRF-7 siRNA (h) (siIRF-7), Bax-siRNA (h) (siBax), Noxa-
siRNA (h) (siNoxa), or nontarget siRNA (siCon). The
siPLSCR1 (cat# sc-44028), siIFITM1 (cat# sc-44549),
siSTAT1 (cat# sc-44123), siSTAT2 (cat# sc-29492),
siIFNα (cat# sc-63324), siIRF-7 (cat# 38011) and siRNA
negative control (cat# sc-37007) were purchased from
Santa Cruz Biotechnology, and siBax and siNoxa were
purchased from Thermo Fisher Scientific (Pittsburg, PA,
USA). All of the siRNAs were pools of three target-
specific 20 to 25 nt siRNAs. MCF-7:5C or MCF-7 cells
were seeded the night before transfection at a density
of 30% to 50% confluence by the time of transfection.
Twenty nmol of siPLSCR1, siIFITM1, siSTAT1 and siRNA
negative control were used for transfection using Lipofec-
tamine 2000 (Invitrogen, San Diego, CA, USA) according
to the manufacturer’s instructions. Transfected cells were
maintained in culture for two days before harvesting and
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was determined by Western blot analysis.
Short hairpin RNA (shRNA) knockdown
MCF-7:5C cells were transiently transfected with IFITM1-
shRNA plasmid (h) (shIFITM1, cat# sc-44549-SH) or
control-shRNA (shControl, cat# sc-108060) plasmid which
were purchased from Santa Cruz Biotechnology. IFITM1
shRNA plasmid is a pool of three different shRNA plas-
mids. sc-44549-SHA: Hairpin sequence: GATCCCA
CACTTCTCAAACCTTCATTCAAG AGATGAAGGT
TTGAGAAGTGTGTTTTT. Corresponding siRNA se-
quences (sc-44549A): Sense: CACACUUCUCAAACC
UUCAtt; Antisense: UGAAGGUUUGAGAAGUGUGtt.
sc-44549-SHB: Hairpin sequence: GATCCCTGTGACA
GTCTACCATATTTCAAGAGAATA TGGTAGACTGT
CACAGTTTTT. Corresponding siRNA sequences (sc-




Corresponding siRNA sequences (sc-44549C): Sense:
CUGUCUACAGUGUCAUUCAtt; Antisense: UGAAUG
ACACUGUAGACAGtt. MCF-7:5C cells were seeded in
six-well plates and at 50% to 70% confluency were trans-
fected with 3 μg of shIFITM1 or shControl plasmid using
Lipofectamine 2000 (Invitrogen, San Diego, CA, USA)
according to the manufacturer’s instructions. The trans-
fected cells were incubated for 24 or 48 hours and the ef-
ficiency of the shRNA knockdown was determined by
Western blot analysis and real-time PCR. The knock-
down cells were then used for additional experiments.
Cell migration and invasion assay
Cell migration was measured in a Boyden chamber using
Transwell filters obtained from Corning (Cambridge,
MA, USA). MCF-7:5C cells (1 × 105) in 0.5 mL serum-
free medium were placed in the upper chamber, and the
lower chamber was loaded with 0.8 mL medium con-
taining 10% charcoal-stripped FBS. Cells that migrated
to the lower surface of the filters were stained with
Wright Giemsa solution, and five fields of each well were
counted after 24 hours of incubation at 37°C with 5%
CO2. Three wells were examined for each condition and
cell type, and the experiments were repeated in triplicate.
Cell invasion assay was performed using a Chemicon Cell
Invasion kit (Chemicon International, Temecula, CA,
USA) in accordance with the manufacturer’s protocol.
Cells (1 × 105/mL) were seeded onto 12-well cell culture
chambers using inserts with 8 μM pore size polycarbonate
membrane over a thin layer of extracellular matrix (ECM).
Following incubation of the plates for 24 hours at 37°C,
cells that had invaded through the ECM layer and migrated
to the lower surface of the membrane were stained andcounted under the microscope in at least ten different
fields and photographed.
RNA isolation and RT-PCR analysis
Total RNA was isolated from cultured cells using the
RNeasy® Mini Kit (Qiagen, Venlo, Netherlands) accord-
ing to the manufacturer’s procedure. First strand cDNA
synthesis was performed from 2.5 μg total RNA using
Super- Script Reverse Transcriptase (Invitrogen). cDNA
was amplified in a 15-μl PCR mixture containing 1 mM
dNTPs, 1× PCR buffer, 2.5 mM MgCl2 and 1 U DNA
Taq polymerase (Promega, Madison, WI, USA) with 25
pmol of primers specific for human PLSCR1 (sense: 5′-
CATTCACCGGGCTCTCTAC-3′; antisense: 5′-GGCA
GCTGGGCA ATCTTGCA-3′), IFITM1 (sense: 5′-GGA
TTTCGGCTTGTCCCGAG-3′; antisense: 5′- CCATG
TGGAAGGGAGGGCTC-3′), IRF-9 (sense: 5′-TTCTG
TCCCTGGTGTAGAGCCT-3′, antisense: 5′- TTTCAG
GACACGATTATCACGG-3′), IRF-7 sense: 5′-GAGC
CCTTACCTCCC CTGTTAT-3′, antisense: 5′’-CCAC
TGCAGCCCCTCATAG-3′, IFI27 (sense: 5′- GCCT
CTGG CTCTGCCGTAGTT-3′, antisense: 5′-ATGGA
GGACGAGGCGATTCC-3′), IFIT1 (sense 5′-TCTCA
GAGGAGCCTGGCTAA-3′, antisense 5′-CCAGACTA
TCCTTGACCTGATGA-3′), MX1 (sense: 5′-CTTTCC
AGTCCAGCTCGGCA-3′, antisense: 5′-AGCTGCTGG
CCGTACGT CTG-3′), OAS1 sense: 5′-TGAGGTCC
AGGCTCCACGCT-3′, antisense: 5′-GCAGGTC GGT
GCACTCCTCG-3′), STAT1 (sense: 5′-GGCACCAGA
ACGAATGAGGG-3′, antisense: 5′-CCATCGTGCACA
TGGTGGAG-3′, STAT2 (sense: 5′-GCAGCACAATTT
GCGGAA-3′, antisense: 5′-ACAGGTGTTTCGAGAAC
TGGC-3′). The condition in the logarithmic phase of
PCR amplification was as follows: five minutes initial de-
naturation at 94°C, one minute denaturation at 94°C,
35 seconds annealing at 67°C and 1.5 min extension at
72°C for 30 cycles. The number of amplification cycles
during which PCR product formation was limited by
template concentration was determined in pilot experi-
ments. PUM1 was used as the internal control (sense:
5′-TCACCGAGGCCCCTCTGAACCCTA-3′; antisense:
5′-GGCAGTAATCTCCTTCTGCATCC T-3′). The re-
producibility of the quantitative measurements was eval-
uated by three independent cDNA syntheses and PCR
amplification from each preparation of RNA. Densito-
metric analysis was performed using Scion Image soft-
ware (Scion Corp, Frederick, MD, USA), and the relative
mRNA expression level was determined as the ratio of
the signal intensity of the target to that of PUM1.
Tissue microarray construction and immunohistochemistry
Paraffin-embedded de-identified human breast cancer
tissue samples were collected from the Tumor Bank fa-
cility at The Research Institute of Fox Chase Cancer
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Kansas Medical Center (KUMC) and the protocols were
reviewed and approved by the Institutional Review
Board at Fox Chase Cancer Center and KUMC. The
archived tumor samples were collected from patients
(N = 40) who were initially treated with Arimidex and
either responded or responded but then developed recur-
rence disease with an average time to disease progression
(TTP) of 93 months. Patients provided written informed
consent for the use of their tumor samples. Tissue micro-
array (TMA) slides were constructed from 40 matching
primary and AI-resistant tumors using duplicate cores
of 0.6 mm per tumor sample. Normal mammary tissue
samples (N = 10) were also included on the TMA. For
immunohistochemistry assays, tissue microarray slides
were incubated at room temperature for 20 minutes with
antibodies against IFITM1 (Santa Cruz Biotechnology)
and PLSCR1 (Chemicon Inc.) applied at 1:100 dilution in
antibody diluent (Dako, Carpenteria, CA, USA). A sec-
ondary anti-mouse antibody polymer conjugated with
HRP (Dako) was applied for 30 minutes and 3,3′-diamino-
benzidine (DAB) was used to produce visible, localized
staining viewable with light microscopy. Sections without
primary antibody served as negative controls. A semi-
automated quantitative image analysis system, ACIS II
(ChromaVision Medical Systems, Inc., San Juan Capistrano,
CA, USA), was used to quantitate the staining of the
TMA slides. For immunohistochemical analysis, the
scores were determined by combining the proportion of
positively stained tumor cells and the intensity of stain-
ing, giving rise to a Staining Index (SI) value for each
sample. The proportion of positively stained tumor cells
was graded as follows: 0 (<5% positively stained tumor
cells), 1 (5% to 25% positive tumor cells), 2 (25% to 50%
positive tumor cells), 3 (50% to 75% positive tumor cells)
and 4 (>75% positive tumor cells). The intensity of staining
was recorded on a scale of 0 (no staining), 1 (weak stain-
ing, light brown), 2 (moderate staining, yellowish brown)
and 3 (strong staining, brown). The SI value was calcu-
lated as follows: SI = staining intensity × proportion of
positively stained tumor cells. Scores were evaluated com-
paratively for the expression of IFITM1 and PLSCR1 in
breast tumors by SIs (scored as 0, 1, 2, 3, 4, 6 or 9). An op-
timal cutoff value was identified, and the SI score of ≥6
was used to define tumors with high expression and SI ≤3
as tumors with low expression of IFITM1 and PLSCR1.
Immunohistochemistry (IHC) analysis was also performed
on MCF-7, T47D and MCF-7:5C breast cancer cells to
detect IFITM1 and PLSCR1 protein expression. Cells
were cultured in their appropriate medium, harvested
by cell scraper before reaching confluence, washed twice
with PBS and fixed in 10% formalin for 16 hours. Each
cell line was pelleted and made into a cell block. One H
& E stain and two IHC stains for PLSCR1 and IFITM1were subsequently performed for each cell line. Pretreat-
ments consisted of enzyme digestion or other heat
mediated retrieval methods. Sections were stained on
a Dako Autostainer using either an Envision PlusHRP
polymer (Dako) or horse anti-mouse IgG-biotin (Vector
Laboratories, Inc. Burlingame, CA, USA), streptavidin-
HRP (Jackson Labs) and AEC (Dako), and counterstained
in hematoxylin.
Statistical analysis
At least three separate experiments were performed for
each measurement. All quantitative data were expressed
as mean S.D. Comparisons between two groups were
analyzed using two-way analysis of variance (ANOVA),
with P value of <0.05 considered to be statistically
significant.
Results
IFITM1 and PLSCR1 are constitutively overexpressed in
AI-resistant human breast cancer cells and AI-resistant
tumors
Microarray studies previously revealed that the inter-
feron signaling pathway was altered in AI-resistant
breast cancer cells compared with AI-sensitive cells [17].
To understand better the role of the interferon signaling
pathway in AI-resistant breast cancer we measured the
basal expression of two well-known interferon stimu-
lated proteins, IFITM1 and PLSCR1, in AI-resistant
MCF-7:5C breast cancer cells and AI-sensitive MCF-7
and T47D cells. Our data showed that IFITM1 and
PLSCR1 were constitutively overexpressed at the protein
(Figure 1A) and mRNA level (Figure 1B) in AI-resistant
MCF-7:5C cells but were almost undetectable at the pro-
tein and mRNA level in AI-sensitive MCF-7 and T47D
cells. Notably, we also found that several other ISGs in-
cluding IFI27, IFIT1, OAS1, MX1, IRF-7, IRF-9, STAT1
and STAT2 were constitutively overexpressed in AI-
resistant MCF-7:5C cells compared with MCF-7 cells
(Additional file 1: Figure S1). Immunocytochemistry
(ICC) staining of MCF-7, T47D and MCF-7:5C cells also
showed that IFITM1 and PLSCR1 were overexpressed in
MCF-7:5C cells compared to MCF-7 and T47D cells
(Figure 1C). Next, we investigated the clinical signifi-
cance of IFITM1 and PLSCR1 expression in AI-resistant
(recurrence) breast cancer by performing IHC staining
on normal breast tissue, primary breast tumors (N = 40)
and AI-resistant recurrence breast tumors (N = 40). We
found that IFITM1 and PLSCR1 proteins were overex-
pressed in 90% of the AI-resistant (recurrence) tumors
(36 of 40 samples) compared with only 20% of the pri-
mary tumors (8 out of 40 samples); however, in normal
breast tissue PLSCR1 and IFITM1 proteins were un-
detectable (Figure 1D). As shown in Table 1, stained









































































































Figure 1 IFITM1 and PLSCR1 expression in endocrine-sensitive and AI-resistant breast cancer cells. (A) The cell extracts isolated from the
indicated cell lines (endocrine sensitive-T47D/MCF-7, AI-resistant MCF-7:5C) were detected by Western blot analysis for PLSCR1 and IFITM1 protein
and β-actin as a loading control. (B) Total RNA was extracted from each cell line and IFITM1 (upper panel) and PLSCR1 (lower panel) mRNA was
determined by real-time PCR. Fold change was determined for each cell line relative to the internal control gene PUM1. Each value is a mean ± SD from
three experiments. *P <0.05 (C) Relative intensity of the IFITM1 or PLSCR1 in T47D, MCF-7 and MCF-7:5C cells were determined by immunocytochemistry
(ICC) staining. (D) Immunohistochemistry (IHC) staining for IFITM1 or PLSCR1 was performed on tissue microarrays generated from normal breast tissue
(left panel), primary breast tumor tissue (middle panel) and recurrence breast tumor tissue (right panel). For immunohistochemical analysis, the scores
were determined by combining the proportion of positively stained tumor cells and the intensity of staining, giving rise to a Staining Index (SI) value for
each sample. The proportion of positively stained tumor cells was graded as follows: 0 (<5% positively stained tumor cells), 1 (5% to 25% positive tumor
cells), 2 (25% to 50% positive tumor cells), 3 (50% to 75% positive tumor cells) and 4 (>75% positive tumor cells). Representative photomicrographs were
taken using a phase-contrast microscope (original magnification, ×200). AI, aromatase inhibitor; IFITM1, interferon induced transmembrane protein1;
PLSCR1, phospholipid scramblase 1; SD, standard deviation.
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PLSCR1 (SI score = 0); primary tumors showed medium
staining for IFITM1 and PLSCR1 which correlated with
low expression (SI score of ≤3); and AI-resistant (recur-
rence) tumors showed very strong staining for IFITM1
and PLSCR1 which correlated with high expression of
both proteins (SI score of ≥6). Taken together, these re-
sults demonstrate that interferon regulated genes are
constitutively overexpressed in AI resistant breast cancerand they suggest that interferon signaling might be
deregulated in the resistant cells.
IFITM1 and PLSCR1 are localized primarily in the
cytoplasm in AI-resistant cells
Previous studies have shown that IFITM1 and PLSCR1
localize primarily in the plasma membrane [38,39]; how-
ever, these proteins can also translocate to the nucleus
and bind genomic DNA. We examined the cellular
Table 1 Staining intensity of IFITM1 and PLSCR1
expression in normal and breast tumor tissues
Tissue Type Staining
Intensity IFITM1 PLSCR1
Normal tissues No stain 10/10 9/10
Weak 0/10 1/10
Strong 0/10 0/10
Primary tumors No stain 32/40 32/40
Weak 8/40 8/40
Strong 0/40 0/40
Recurrence tumors No stain 0/40 0/40
Weak 4/40 2/40
Strong 36/40 36/40
Staining intensity was calculated for IFITM1 and PLSCR1 expression in normal
breast tissue (N = 10), primary breast tumors (N= 40), and AI-resistant/recurrence
breast tumors (N = 40) as described in Methods. AI, aromatase inhibitor; IFITM1,































Figure 2 Subcellular localization of IFITM1 and PLSCR1 in MCF-7
and MCF-7:5C breast cancer cells. Immunofluorescence staining was
performed on parental MCF-7 and AI-resistant MCF-7:5C cells to assess
the subcellular localization of (A) IFITM1 or (B) PLSCR1. Cells were
seeded in six-well chamber slides and after 24 hours were analyzed
for immunofluorescence staining. (C) The whole-cell lysates, nuclear
and cytoplasmic/membrane fractions of MCF-7 and MCF-7:5C cells
were detected by Western blot analysis for IFITM1 or PLSCR1 protein
with β-actin and lamin B as controls. AI, aromatase inhibitor; IFITM1,
interferon induced transmembrane protein1; PLSCR1, phospholipid
scramblase 1.
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MCF-7:5C cells and AI-sensitive MCF-7 cells using im-
munofluorescence (IF). Our results showed that IFITM1
(Figure 2A) and PLSCR1 (Figure 2B) were highly expressed
in resistant MCF-7:5C cells compared to parental MCF-7
cells and that both proteins localized primarily in the
cytoplasm with minor nuclear localization. Western
blot analysis of fractionated MCF-7 and MCF-7:5C cells
confirmed that IFITM1 and PLSCR1 were overexpressed
in MCF-7:5C cells compared with MCF-7 cells and that
both proteins were localized primarily in the cytoplasm
with some nuclear localization observed for IFITM1
(Figure 2C).
IFNα drives overexpression of IFITM1 and PLSCR1 in
AI-resistant MCF-7:5C cells
Binding of interferon alpha (IFNα) to the IFN alpha
Type 1 receptor (IFNAR1) complex initiates a signaling
cascade comprising phosphorylation and dimerization of
STAT1/2 molecules followed by their translocation to
the nucleus, where they regulate the expression of ISGs.
To investigate whether constitutive overexpression of
IFITM1 and PLSCR1 in resistant MCF-7:5C cells is
driven by the canonical IFNα signaling pathway, we first
measured intracellular IFNα level in the supernatant and
lysate of AI-resistant MCF-7:5C and parental MCF-7
cells using ELISA. As shown in Figure 3A, IFNα protein
level was significantly higher in the supernatant and lys-
ate of resistant MCF-7:5C cells compared to parental
MCF-7 cells. IFNα mRNA expression was also signifi-
cantly elevated in resistant MCF-7:5C cells compared to
MCF-7 cells (Figure 3B). Next, we used a neutralizing
antibody against the type 1 interferon receptor, IFNAR1/
2, to see whether blocking the receptor reduces IFITM1and PLSCR1 expression in the resistant cells. As shown
in Figure 3C, the IFNAR1/2 neutralizing antibody, α-
IFNAR-Ab, markedly reduced the basal expression of
Figure 3 (See legend on next page.)
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Figure 3 Elevated level of intracellular IFNα drives constitutive overexpression of IFITM1. (A) ELISA analysis of baseline expression of IFNα
in cell lysates and supernatant in MCF-7:5C and MCF-7 cells. Cells (1 x 106) were seeded in a six-well plate in their standard culture media and
after 48 hours cells were harvested and the supernatant and pellets were collected. Cell pellets were then lysed by sonication in RIPA buffer
containing protease inhibitors. IFNα was measured in the supernatants and cell lysates by ELISA as described in Methods. All the illustrated data
were performed in duplicate and are expressed as mean values of three independent experiments ± SD. (B) Measurement of IFNα mRNA was
determined by real-time PCR. Fold change was calculated by means of the ΔΔCT method using PUM1 as an internal control. Values are displayed
as relative to MCF-7 cells and are means of triplicate measurements ± SD in three independent experiments. (C) Blockade of type 1 interferon
receptor, IFNAR1, using neutralizing antibody MAB1155, in MCF-7 and MCF-7:5C cells. Cells were pretreated with 5 μg/mL anti-IFNAR1/2 for
4 hours and then treated with 20 U/mL human recombinant IFNα for 24 hours. Cells were analyzed by Western blot to assess IFITM1, PLSCR1 and
β-actin protein level. Results shown are representative of three independent experiments. The protein levels were quantified using the ImageJ
software (downloaded from NIH website [40]) and normalized as the ratio related to β-actin. *P <0.05 or **P <0.01 versus control. (D) siRNA knock-
down of IRF-7 expression in MCF-7:5C cells. Cells were transiently transfected with siRNA targeting IRF-7 and after 24 hours knockdown was verified
at the mRNA and protein level via RT-PCR and Western blot analyses. (E) Effect of IRF-7 knockdown on IFNα expression in resistant MCF-7:5C cells.
Cells were transiently transfected with siRNA targeting IRF-7. After 24 hours, IFNα mRNA and IFNα protein expression were determined by real-time
PCR and ELISA, respectively. Data shown for RT-PCR is expressed as fold change over cells transfected with control siRNA. Values are displayed
as means ± SD of three independent experiments performed in triplicate. *P <0.05 or **P <0.01. (F) The effect of IFNα or IRF-7 knockdown on
IFITM1, p-STAT2, STAT2, p-STAT1, STAT1, and IRF-7 protein expression in resistant MCF-7:5C cells. Cells were transiently transfected with siIFNα,
siIRF-7 or siCon for 48 hours and Western blot analysis was performed on lysates. Results shown are representative of two independent experiments
IFITM1, interferon induced transmembrane protein1; IFNAR1, IFN alpha Type 1 receptor; NIH, National Institutes of Health; PLSCR1, phospholipid
scramblase 1; SD, standard deviation.
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completely blocked exogenous IFNα induction of IFITM1
and PLSCR1 in parental MCF-7 cells. We further tested
whether suppression of the intracellular IFNα level is cap-
able of reducing IFITM1 and PLSCR1 expression in the re-
sistant cells. Induction of IFNα production is primarily
controlled at the transcription level by the transcription
factor IRF-7, hence, we performed siRNA knockdown of
IRF-7 to suppress intracellular IFNα level in the resistant
cells. We should note that IRF-7 mRNA (Additional file 1:
Figure S1) and IRF-7 protein (Figure 3D, bottom panel)
were constitutively overexpressed in resistant MCF-7:5C
cells compared to parental MCF-7 cells. As shown in
Figure 3D, siIRF-7 markedly reduced IRF-7 mRNA and
protein expression in resistant MCF-7:5C cells and it sig-
nificantly decreased IFNα protein (Figure 3E, top) and
IFNα mRNA level (data not shown) in these cells. In
addition, we found that siRNA knockdown of IFNα re-
duced its protein level in the supernatant by 100% and in
the lysate by 50% (Figure 3E, bottom). Furthermore, we
found that siRNA knockdown of both IFNα and IRF-7
completely reduced IFITM1, PLSCR1, p-STAT1 and
p-STAT2 protein expression in the resistant cells (Figure 3F).
Taken together, these data indicate that IFNα is signifi-
cantly elevated in the supernatant and lysate of AI-
resistant MCF-7:5C breast cancer cells and that activation
of the canonical IFNα/IFNAR signaling pathway plays a
critical role in driving the constitutive overexpression of
IFITM1 and other ISGs in the resistant cells.
Dysregulation of type 1 IFNα signaling in AI-resistant
MCF-7:5C cells
Since IFITM1 and PLSCR1 were constitutively overex-
pressed in the resistant cells, we wanted to assess thefunctional integrity of the interferon signaling pathway
in the resistant cells compared to parental MCF-7 cells.
Cells were treated with 1,000 U/ml of IFNα for 0
to 24 hours and protein levels of IFITM1, PLSCR1,
STAT1, p-STAT1 (Y701), STAT2, p-STAT2 (Tyr690)
and IFNAR1 were determined by Western blot analysis.
We found that in parental MCF-7 cells, IFNα treatment
significantly increased PLSCR1, IFITM1, STAT1, p-STAT1,
STAT2, p-STAT2 and IFNAR1 protein expression in a
time-dependent manner with maximum induction of
PLSCR1, IFITM1, STAT1, STAT2 and IFNAR1 observed
at 24 hours and for p-STAT1 and p-STAT2 at 30 minutes
(Figure 4A, left panel). In contrast, we found that IFITM1
and PLSCR1 were constitutively overexpressed in resistant
MCF-7:5C cells and that treatment with exogenous IFNα
only increased p-STAT and p-STAT2 protein; however, it
did not further increase the level of IFITM1, PLSCR1 or
STAT1 at any of the time points except at 24 hours where
we detected a <2-fold increase in PLSCR1 and IFITM1
(Figure 4A, right panel; Additional file 2: Figure S2). A
similar trend was observed at the mRNA level for IFITM1,
PLSCR1 and STAT1 in resistant MCF-7:5C cells compared
to parental MCF-7 cells (Additional file 3: Figure S3). In
MCF-7 cells, exogenous IFNα induced IFITM1 mRNA by
approximately 374-fold, PLSCR1 mRNA by approximately
9-fold and STAT1 mRNA by approximately 11-fold at
48 hours, whereas, in resistant MCF-7:5C cells, treatment
with IFN-α induced IFITM1 mRNA by approximately 3-
fold, PLSCR1 mRNA by approximately 2-fold, and STAT1
mRNA by approximately 2-fold (Additional file 3:
Figure S3). These findings suggest that IFITM1, PLSCR1
and STAT1 are constitutively overexpressed in the resistant
cells due to dysregulation of interferon signaling, whereas,
in parental MCF-7 cells, the interferon signaling pathway
Figure 4 (See legend on next page.)
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Figure 4 Activation of interferon signaling pathway in parental MCF-7 and AI-resistant MCF-7:5C cells in response to INFα. (A) MCF-7
(left panel) and MCF-7:5C (right panel) cells were incubated with IFNα (1000 U/ml) for the indicated time points. The cell extracts were examined
by Western blotting using anti-PLSCR1, anti-IFITM1, anti-STAT1, anti-phospho-STAT1 (Y701), anti-IFNAR1, anti-STAT2, anti-phospho-STAT2 (Tyr690)
and anti-β-actin. (B) Cellular localization of IFITM1 and PLSCR1 in MCF-7 and MCF-7:5C cells following IFNα treatment. Cells were treated for 24 hours
with IFNα (1000 U/ml) and then analyzed for immunofluorescence staining of IFITM1 and PLSCR1 (original magnification 200×). (C) MCF-7 and
MCF-7:5C cells were treated with IFNα (1000 U/ml) for 24, 48, 72 and 96 hours and cell proliferation was measured by the MTT assay. All the
illustrated data are expressed as mean values of three independent experiments. Standard deviations are shown. *P <0.05; **P <0.01. AI, aromatase
inhibitor; IFITM1, interferon induced transmembrane protein1; IFNAR1, IFN alpha Type 1 receptor; MTT, 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium
bromide; PLSCR1, phospholipid scramblase 1; STAT1,2, Signal transducer and activator of transcription 1,2.
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other ISGs is tightly controlled.
Next, we examined whether IFNα treatment facilitated
translocation of IFITM1 and PLSCR1 from the cyto-
plasm to the nucleus. As shown in Figure 4B, treatment
with IFNα significantly increased IFITM1 and PLSCR1
protein expression in MCF-7 cells but not in AI-
resistant MCF-7:5C cells; however, it did not cause
IFITM1 or PLSCR1 to translocate from the cytoplasm to
the nucleus in either cell line. Interestingly, cell viability
assay showed that IFNα treatment significantly inhibited
the proliferation of both MCF-7 and MCF-7:5C cells in
a time-dependent manner (Figure 4C) and that AI-
resistant MCF-7:5C cells were slightly more sensitive to
the growth inhibitory effect of IFNα than MCF-7 cells.
Knockdown of IFITM1 induces cell death in AI-resistant
MCF-7:5C breast cancer cells
Previous studies have reported that IFITM1 and PLSCR1
exert both antiproliferative and proliferative effects in
different types of cancer cells; however, their functional
significance in AI-resistant breast cancer cells is not
known. To determine the functional significance of
IFITM1 and PLSCR1 in AI-resistant MCF-7:5C breast
cancer cells, we transiently transfected MCF-7:5C cells
with siRNA targeting IFITM1 or PLSCR1 and we
assessed the effect of their knockdown on cell prolifera-
tion, cell death and cell cycle progression. Western blot
analysis confirmed knockdown of IFITM1 and PLSCR1
protein in AI-resistant MCF-7:5C cells at 24, 48 and
72 hours post-transfection (Figure 5A). Cell viability
assay showed that knockdown of IFITM1, but not
PLSCR1, significantly inhibited the proliferation of AI-
resistant MCF-7:5C cells at 72 hours relative to control
cells and it markedly enhanced the inhibitory effect of E2
in these cells (Figure 5B). The growth inhibitory effect of
IFITM1-knockdown in AI-resistant MCF-7:5C cells was
due to cell death, as demonstrated by annexin V-PI
staining (Figure 5C). Specifically, knockdown of IFITM1
in MCF-7:5C cells increased the total number of dead
cells from 10.8% (siCon) to 35.1% in the IFITM1-
knockdown cells and it enhanced the apoptotic effect of
E2 from 34.6% to 57.1% (Figure 5C). We should notethat the ability of E2 to induce cell death in AI-resistant
breast cancer cells has previously been reported by our
laboratory [11,15,16]; however, this is the first study to
show that suppression of IFITM1 enhances E2-induced
cell death in AI resistant breast cancer cells. Further
analysis indicated that knockdown of IFITM1 signifi-
cantly increased the expression of p21, Bax and Noxa in
AI-resistant MCF-7:5C cells; however, it did not signifi-
cantly alter p53 expression in these cells (Figure 5D). To
validate the specificity and the biological function of
IFITM1 in our resistant cells we used a second shRNA
targeting IFITM1 (Additional file 4: Figure S4). We found
that shRNA knockdown of IFITM1 induced poly ADP
ribose polymerase (PARP) cleavage (Additional file 4:
Figure S4A), reduced cell proliferation (Additional file 4:
Figure S4B) and induced cell death in resistant MCF-7:5C
cells which was further enhanced by the addition of E2
(Additional file 4: Figure S4C). To confirm that IFNα was
responsible for the dysregulation of IFITM1 and that
blocking its function enhances E2-induced cell death, we
knockeddown IFNα expression in resistant MCF-7:5C cells
and then treated the cells with E2 for an additional
96 hours. As shown in Additional file 5: Figure S5, knock-
down of IFNα significantly reduced the proliferation of
MCF-7:5C cells and it significantly enhanced E2-induced
death in these cells at 96 hours. Furthermore, we found
that blocking IFNAR1/2 with a neutralizing antibody also
reduced the proliferation of MCF-7:5C cells and it mark-
edly enhanced E2-induced death in these cells at the same
time point. These findings confirm that IFNα is responsible
for the dysregulated expression of IFITM1 in the resistant
cells and that blocking its function collaborates with E2 to
enhance cell death in these cells. Furthermore, these find-
ings suggest that IFITM1 overexpression provides a sur-
vival advantage to the resistant cells that allows them to
grow in an estrogen-depleted environment and that knock-
down of IFITM1 disrupts the survival pathway in these
cells thus sensitizing them to cell death.
IFITM1 knockdown inhibits migration and invasion of
AI-resistant MCF-7:5C cells
There is evidence that IFITM1 overexpression induces
tumor resistance to natural killer (NK) cells in gastric
Figure 5 (See legend on next page.)
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Figure 5 IFITM1 knockdown increases cell death in AI-resistant breast cancer cells. (A) MCF-7:5C cells were transfected with control siRNA
(siCon), IFITM1 siRNA (siIFITM1) or PLSCR1 siRNA (siPLSCR1) for 24, 48 and 72 hours and cell extracts were subject to Western blotting analysis to
assess IFITM1 and PLSCR1 protein expression. (B) MCF-7:5C cells were transfected with siCon, siIFITM1 (left panel) or siPLSCR1 (right panel) for
24 hours and then treated with 1 nM E2 for an additional 72 hours. Cell proliferation was measured by the MTT assay. All the illustrated data are
expressed as mean values of three independent experiments. Standard deviations are shown. *P <0.05 versus control; #P <0.05 versus E2 treatment.
(C) MCF-7:5C cells were transfected with siCon or siIFITM1 and after 24 hours were exposed to E2 (1 nM) for an additional 96 hours. Cells were then
stained with annexin V-FITC and PI for detection of apoptosis as described in Methods. (D) Cells were treated as described above in (C) and were
analyzed by Western blotting to assess IFITM1, p21, Bax, p53, Noxa and PARP protein expression. Membranes were stripped and reprobed for
β-actin, which was used as a loading control. The protein levels for p21, Bax and Noxa were quantified using the ImageJ software (downloaded from the
NIH website) and normalized as the ratio relate to β-actin. *P <0.05; **P <0.01. AI, aromatase inhibitor; E2, 17β-estradiol; FITC, fluorescein isothiocyanate;
IFITM1, interferon induced transmembrane protein1; IFNAR1, IFN alpha Type 1 receptor; MTT, 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide;
NIH, National Institutes of Health; PARP, poly ADP ribose polymerase; PI, propidium iodide; PLSCR1, phospholipid scramblase 1.
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gastric cancer cells [29]. In addition, overexpression of
IFITM1 has been shown to promote head and neck
tumor invasion by mediating the expression of matrix
metalloproteinases 12 and 13 [32]. To investigate the
role of IFITM1 in breast cancer progression, we exam-
ined the influence of IFITM1 knockdown on migration
and invasion of AI-resistant MCF-7:5C breast cancer
cells. Western blot and real-time PCR analysis con-
firmed that IFITM1 protein and mRNA expression sup-
pressed by siRNA in MCF-7:5C cells compared with
siCon-transfected cells (Figure 6A). Silencing of IFITM1
markedly reduced the migratory ability (Figure 6B) and
invasion capacity (Figure 6C) of AI-resistant MCF-7:5C
cells. The cell migration and invasion counted from 10
randomly selected areas per well at 24 hours showed
that siRNA knockdown of IFITM1 inhibited migration
by 54% (Figure 6B, bar graph) and invasion by approxi-
mately 78% (Figure 6C) compared with siCon-transfected
cells. To confirm that the inhibitory effect of IFITM1
knockdown on migration and invasion was not due to cell
death we measured apoptosis (via flow cytometry) and cell
viability in IFITM1-knockdown MCF-7:5C cells at the
same time point (24 hours) the migration and invasion as-
says were performed. As shown in Figure 6D, IFITM1
knockdown did not induce cell death (top panel) or re-
duce cell viability (bottom panel) at 24 hours; hence, its
inhibitory effect on migration and invasion at 24 hours is
not due to cell death. However, we should note that
knockdown of IFITM1 does cause significant cell death at
72 hours; hence, migration and invasion would be inhib-
ited at the later time points due to cell death. This result
suggests that overexpression of IFITM1 enhances the abil-
ity of AI-resistant MCF-7:5C cells to migrate and invade
and its suppression has the opposite effect.
STAT1 and STAT2 regulate IFITM1 and PLSCR1 expression
in resistant MCF-7:5C cells
STAT1 and STAT2 are members of the signal transduc-
ers and activators of transcription family of transcriptionfactors that play a pivotal role in regulating type I (α/β)
and type II (γ) interferon signaling. In response to either
IFNα or IFNβ stimulation, STAT1 and STAT2 form
homodimers or heterodimers, move to the nucleus and
activate the transcription of interferon response genes.
Since IFITM1 and PLSCR1 are constitutively overex-
pressed in AI-resistant MCF-7:5C cells, we examined
whether knockdown of STAT1 or STAT2 is capable of
altering their expression in MCF-7:5C cells. AI-resistant
MCF-7:5C cells were transiently transfected with control
siRNA (siCon), STAT1 siRNA (siSTAT1) or STAT2
siRNA (siSTAT2) and the effect of knockdown on
IFITM1 and PLSCR1 expression was assessed at 24 and
48 hours using Western blot analysis. As shown in
Figure 7A (left panel), knockdown of STAT1 markedly
reduced IFITM1 and PLSCR1 protein expression in re-
sistant MCF-7:5C cells at 24 and 48 hours, and it signifi-
cantly reduced the proliferation of MCF-7:5C cells, and it
further enhanced the inhibitory effect of E2 in these cells.
STAT2 knockdown also reduced IFITM1 and PLSCR1
protein level in MCF-7:5C cells (Figure 7B, left panel),
and it significantly enhanced the inhibitory effect of E2 in
these cells (Figure 7B, right panel). Furthermore, we
found that knockdown of both STAT1 and STAT2 com-
pletely suppressed IFITM1 and PLSCR1 expression in re-
sistant MCF-7:5C cells (Additional file 6: Figure S6),
thereby confirming a critical role for STAT1 and STAT2
in the regulation of IFITM1 and PLSCR1 expression.
Interestingly, we found that knockdown of proapoptotic
Bax and Noxa enhanced IFITM1 and PLSCR1 expression
in MCF-7:5C cells, however, the mechanism by which
this occurs is currently not known (Figure 7C).
4-Hydroxytamoxifen inhibits IFITM1 expression in
AI-resistant MCF-7:5C cells
Since knockdown of IFITM1 significantly enhanced E2-
induced cell death in AI-resistant MCF-7:5C cells, we
next determined whether IFITM1 expression is regu-
lated by the estrogen receptor (ERα). MCF-7:5C cells
were treated with 1 nM E2, 1 μM of 4-hydroxytamoxifen
Figure 6 (See legend on next page.)
Choi et al. Breast Cancer Research  (2015) 17:6 Page 15 of 23
(See figure on previous page.)
Figure 6 IFITM1 knockdown decreases migration and invasion in AI-resistant MCF-7:5C breast cancer cells. (A) MCF-7:5C cells were transfected
with control siRNA (siCon) or IFITM1 siRNA (siIFITM1) for 24 hours and knockdown of IFITM1 protein expression was confirmed by Western blot (right
panel) and real-time PCR analyses (left panel). Standard deviations are shown. **P <0.01 versus siCon. (B and C) The effect of IFITM1 knockdown on cell
migration (B) and invasion (C) was assessed by transwell migration assay and matrigel invasion assay. Cells that invaded through the Matrigel-coated
transwells were fixed, stained, visualized by light microscopy and photographed. Quantitation of the Transwell assay is also shown (B, right panel). Ten
random fields were counted per insert at 20X. **P <0.01. (D) Effect of IFITM1 knockdown on cell viability in resistant MCF-7:5C cells. Cells were transfected
with siCon or siIFITM1 for 24 hours, then DNA content of cells was analyzed using flow cytometry as described in the Methods section. The arrow is sub
G1 phase apoptosis. MTT assay (bottom panel) was also performed in the IFITM1-knockdown cells at 24 hours. All the illustrated data are expressed as
mean values of three independent experiments. Standard deviations are shown. AI, aromatase inhibitor; IFITM1, interferon induced transmembrane
protein1; MTT, 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide.
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fulvestrant (ICI 182,780), the pure antiestrogen that
downregulates ERα and the expression of IFITM1,
PLSCR1 and ERα were measured by Western blot
analysis. As shown in Figure 8A, E2 and fulvestrant com-
pletely down-regulated ERα protein but did not signifi-
cantly alter IFITM1 or PLSCR1 expression, whereas
4OHT did not down-regulate ERα protein but it signifi-
cantly reduced IFITM1 and PLSCR1 expression in the
resistant cells. Interestingly, we found that 4OHT also
partially blocked the cell death effect of IFITM1-
knockdown in MCF-7:5C cells, as demonstrated by
inhibition of PARP cleavage (Figure 8B). Thus, it is pos-
sible that IFITM1 expression might be regulated by ERα;
however; we do not rule out the possibility that 4OHT
might be exerting an effect on IFITM1 that is independ-
ent of ERα. Further studies are needed to understand
better the mechanism by which 4OHT regulates IFITM1
and whether ERα is involved in the process.
Discussion
Estrogen deprivation by treatment with AIs is the most
effective form of endocrine therapy for postmenopausal
women with estrogen receptor–positive (ER+) breast
cancer. Unfortunately, the majority of patients treated
with AIs eventually develop resistance. While the mech-
anism by which endocrine resistance occurs is still not
completely known, there is evidence to suggest that dys-
regulation in the interferon signaling pathway might play
a role in the process. Indeed, studies have reported a
strong correlation between constitutive expression of
ISGs and resistance to radiotherapy and chemotherapy
in several types of human cancers including breast can-
cer, ovarian cancer, lung cancer and lymphatic leukemia
[41-44]. Notably, Dunbier and coworkers [45] recently
reported on the poor anti-proliferative response to AI
treatment in postmenopausal patients whose tumors
expressed high baseline expression of immune response
genes; however, these investigators did not examine
interferon signaling in AI-resistant breast tumors. In the
present study, we have demonstrated that interferon sig-
naling is dysregulated in AI-resistant breast cancer cellsand AI-resistant/recurrence tumors and that several
interferon response genes including; IFITM1, PLSCR1,
STAT1, STAT2, IRF-7, IRF-9, IFIT1, OAS1 and MX1 are
constitutively overexpressed in AI-resistant breast cancer
cells. In particular, we showed that IFITM1 and PLSCR1
were overexpressed at the mRNA and protein level in
AI-resistant MCF-7:5C cells compared with AI-sensitive
MCF-7 and T47D cells and that suppression of IFITM1,
and to a lesser extent PLSCR1, significantly inhibits the
proliferation of AI-resistant MCF-7:5C cells and blocked
the ability of these cells to invade and migrate. Most
interestingly, we found that silencing of IFITM1,
PLSCR1 and STAT1 significantly enhanced E2-induced
cell death in AI-resistant MCF-7:5C cells which was as-
sociated with induction of p21, Bax, and Noxa. Add-
itionally, we found that constitutive overexpression of
IFITM1 and PLSCR1 was driven by IFNα signaling
through the canonical IFNAR1/2/STAT1/STAT2 signal-
ing pathway and that knockdown of STAT1 and STAT2
and blockade of IFNα function dramatically suppressed
IFITM1 and PLSCR1 expression in the resistant cells.
To our knowledge, this is the first study to demonstrate
a link between dysregulation of the interferon signaling
pathway and AI resistance and it suggests that targeting
IFITM1 might be an effective strategy to block cell pro-
liferation and enhance E2-induced cell death in AI-
resistant breast cancer cells.
Type I interferons (IFNs α and β) are known to drive
the expression of ISGs that encode proteins that pos-
sess anti-viral, anti-proliferative, pro-apoptotic and pro-
inflammatory functions; however, many experimental
data have shown that high expression of IFN-induced
genes, including STAT1 itself, promotes tumor growth,
metastasis and resistance to chemotherapy and radiation
[23,44,46,47]. Normally, IFNs induce rapid activation of
STATs through phosphorylation on the C-terminal tyro-
sine residues (Y701 for STAT1 and Y690 for STAT2)
which drives the expression of ISGs [19]. Several import-
ant negative feedback mechanisms collaborate to termin-
ate the expression of these genes several hours after IFN
stimulation; for example, expression of the potent nega-

















































































































































































































































Figure 7 STAT1/STAT2 knockdown reduces IFITM1 and PLSCR1 expression. (A and B) MCF-7:5C cells were transfected with sicontrol (siCon),
STAT1 siRNA (siSTAT1) or STAT2 siRNA (siSTAT2) and STAT1, STAT2, IFITM1 and PLSCR1 protein levels were assessed at 24 and 48 hours by
Western blot analysis (left panels). Transfected cells were also treated with E2 for an additional 24 and 48 hours and the above mentioned
proteins were also measured (a and b, left panels). (A, B) Cell proliferation was measured in siSTAT1-knockdown and STAT2-knockdown
cells in the presence or absence of E2 by cell titer blue assay (right panels). Each value is a mean ± SD from three experiments. *P <0.05 or
**P <0.01 versus the control; #P <0.05 versus E2 treatment. (C) MCF-7:5C cells were transfected with Bax siRNA (siBax) or Noxa siRNA (siNoxa) for
24 hours and then treated with 1 nM E2 for an additional 24, 48 or 72 hours. Cells were harvested and analyzed for Bax, PLSCR1, Noxa, and
IFITM1 protein expression by Western blot. Membranes were stripped and reprobed for β-actin, which was used as a loading control. E2,
17β-estradiol; IFITM1, interferon induced transmembrane protein1; PLSCR1, phospholipid scramblase 1; SD, standard deviation; STAT1,2, Signal
transducer and activator of transcription 1,2.



























































































Figure 8 Tamoxifen downregulates IFITM1 and PLSCR1 expression. (A, upper panel) MCF-7:5C cells were treated with E2 (1 nM), 4OHT
(1 μM) or fulvestrant (1 μM) for 72 hours. The cell extracts were examined by Western blotting using anti-PLSCR1, anti-IFITM1, anti-ERα and
anti-β-actin. (A, lower panel) IFITM1 and PLSCR1 protein levels were quantified using the ImageJ software (downloaded from the NIH website)
and normalized to β-actin. (B) Cells were transfected with siCon, siPLSCR1 or siIFITM1 for 24 hours and then treated with 1 nM E2 or 1 μM
4-hydroxytamoxifen (4OHT) for an additional 24 hours. Cells were then harvested and analyzed by Western blotting to assess PLSCR1, IFITM1,
PARP and β-actin protein levels. All the illustrated data are expressed as mean values of three independent experiments. Standard deviations
are shown. *P <0.05 versus control; #P <0.05 versus 4OHT treatment. E2, 17β-estradiol; ERα, estrogen receptor α; IFITM1, interferon induced
transmembrane protein1; NIH, National Institutes of Health; PARP, poly ADP ribose polymerase; PLSCR1, phospholipid scramblase 1.
Choi et al. Breast Cancer Research  (2015) 17:6 Page 18 of 23Based on our studies, we observed several ISGs including
IFITM1, PLSCR1, IFIT1, IFI23, IRF-7, IRF-9, STAT1,
STAT2, MX1 and OAS1 were overexpressed approxi-
mately 10- to 300-fold in AI-resistant MCF-7:5C cells
compared to AI-sensitive parental MCF-7 cells (Additional
file 1: Figure S1). Furthermore, we found that in parental
MCF-7 cells, exogenous addition of recombinant IFNα ro-
bustly induced the expression of IFITM1, PLSCR1 and
STAT1 (10- to 200-fold) within minutes to hours, whereas,
in resistant MCF-7:5C cells, exogenous IFNα only in-
creased IFITM1, PLSCR1, and STAT1 expression by 2- to
3-fold compared to basal level (Figure 4A, Fig. S2, Fig. S3).
This finding suggests that in parental MCF-7 cells, IFITM1
and other ISGs, are not expressed at the basal level unless
stimulated by exogenous IFNα; however, in AI-resistant
MCF-7:5C cells, IFITM1, PLSCR1 and other ISGs are con-
stitutively overexpressed possibly due to an elevated level
of IFNα in the cells. Notably, we detected significantly
elevated levels of IFNα in the supernatant and lysate
of AI-resistant MCF-7:5C cells compared to parental
MCF-7 cells and knockdown of IFNα along with neu-
tralizing antibody blockade of the receptor (IFNAR1/2)
almost completely reduced IFITM1, PLSCR1, p-STAT1
and p-STAT2 expression in the resistant cells, thussuggesting a critical role for the IFNα canonical signal-
ing pathway in driving the constitutive expression of
the ISGs in the resistant cells. Sustained expression of
ISGs and their encoded proteins was previously thought
to be deleterious to cell survival [19]; however, recent
studies suggest that sustained expression of a subset of
ISGs and their encoded proteins might provide a sur-
vival advantage to cells [49]. We should note that ER-
positive breast cancer cells are dependent on estrogen
for survival and growth and when they are deprived of
estrogen they tend to die. Long term, however, some
breast cancer cells develop strategies to allow them to
survive and grow in an estrogen-depleted environment
[10-12,15,16]. In our working model shown in Figure 9,
we propose that in AI-resistant MCF-7:5C breast can-
cer cells, the transcription factor IRF-7 which is a key
regulator of IFNα, is dramatically upregulated and that
increased IRF-7 expression in the resistant cells stimu-
lates the production of IFNα which is then secreted
from the cells and binds to the IFNAR1/2STAT1/
STAT2/IRF-9 complex to induce the expression of ISGs
(that is, IFITM1, PLSCR1, IFIT1, IFI21, OAS1, MX1,
STAT, STAT2, IRF-7, IRF-9). Thus, it is possible that
the constitutive overexpression of the ISGs provides a
Figure 9 Schematic diagram depicting the proposed mechanism of ISG expression in AI-resistant MCF-7:5C cells. ER-positive breast
cancers are dependent on estrogen for survival and growth and when these cancer cells are deprived of estrogen they tend to die. Long term,
however, some breast cancer cells develop strategies to allow them to survive and grow in an estrogen-depleted environment. In our working
model, we propose that long term estrogen deprivation of ERα positive breast cancer cells elicits a stress response in the cell which can possibly
result in increased expression and activation of IRF-7, a known stress response gene. The activated IRF-7 enters the nucleus and binds the IFNα
promoter at the IRF binding-element (IRFE) and ISRE sites, resulting in IFNα production and secretion from the cell. IFNα then binds to its cell
surface receptor IFNAR1/2 which initiates JAK phosphorylation of the STAT proteins and association with IRF-9, forming the activated ISGF3 complex
(p-ISGF3). The BAF complex remodels the chromatin around prospective ISGs and p-ISGF3 is imported into the nucleus where it binds to the
exposed ISRE sites in ISG promoters. This results in the sustained/constitutive overexpression of numerous ISGs including IFITM1 and IRF-7,
which initiates further IFNα production and thus provides autocrine cytokine signaling, reinforcing the production and accumulation of ISGs.
The ISGs are pro-survival and so facilitate cell survival and proliferation under the stressful (estrogen depleted) conditions. Loss of expression of
the ISGs reduces the ability of the resistant cells to survive in an estrogen-depleted environment thus causing them to die. AI, aromatase
inhibitor; ER, estrogen receptor; IFITM1, interferon induced transmembrane protein1; IRF-7, IFN regulatory factor 7; ISGs, interferon stimulated
genes; ISREs, IFN-stimulated response elements; JAK, Janus kinase 1 and 2; STAT, Signal transducer and activator of transcription.
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them to adapt and grow in an estrogen-depleted envir-
onment. The fact that knockdown of IFNα dramatically
reduced IFITM1 expression in the resistant cells and its
loss significantly induced cell death highlights the po-
tential dependency of the resistant cells on elevated
IFNα to maintain their resistant phenotype and to drive
the constitutive overexpression of IFITM1 and the
other ISGs in the cells. We should note that elevated
IFN production has previously been reported in many
pathological conditions, such as chronic inflammation
and cancer, as well as in virus infections [50]. In cancers,
IFN production is thought to be increased by infiltrating
immune cells or by the cancer cells themselves [51].While our studies identified a panel of ISGs that were
constitutively overexpressed in our AI-resistant breast
cancer cells, IFITM1 was the most functionally signifi-
cant of the ISGs in the resistant cells. Clinical data indi-
cated that IFITM1 was constitutively overexpressed in
36 out of 40 AI-resistant breast tumor samples and it
was overexpressed in AI-resistant breast cancer cells ap-
proximately 20- to 30-fold at the mRNA and protein
level. Notably, we found that knockdown of IFITM1 sig-
nificantly increased cell death and it blocked invasion
and migration in the resistant cells. The induction of cell
death in the resistant cells following IFITM1 knockdown
was associated with an increase in p21 and Bax expres-
sion; however, suppression of IFITM1 did not alter p53
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(also known as p21WAF1/Cip1) is a multifunctional protein
that belongs to the cip/kip family of cyclin-dependent
kinase inhibitors and is known to promote G1/S or G2/
M cell cycle arrest and survival in a p53-dependent and
p53-independent manner [52]. In addition, p21 has also
been shown to play a role in apoptosis and it is sug-
gested that its ability to regulate cell cycle arrest versus
apoptosis is influenced by its cellular localization; nu-
cleus accumulation promotes cell cycle arrest whereas
cytoplasmic accumulation inhibits apoptosis [53,54].
Notably, suppression of IFITM1 also induced Bax and
Noxa which are important regulators of mitochondrial-
mediated cell death. Interestingly, previous studies have
reported that p21 counteracts mitochondrial-mediated
apoptosis that relies on Bax and its upstream effector
Puma [55]; however, in our study, p21 induction posi-
tively correlated with Bax and Noxa induction thus sug-
gesting a pro-apoptotic function for p21 in the resistant
cells. We should note that knockdown of IFITM1 also
increased E2-induced cell death in AI-resistant MCF-
7:5C cells. The ability of E2 to induce mitochondrial-
mediated apoptosis in AI-resistant MCF-7:5C cells has
previously been reported by our laboratory [11,17]; how-
ever, this is the first study to show that suppression of
IFITM1 induces p21 and Bax expression and enhances
E2-induced cell death in AI-resistant breast cancer cells.
IFITM1 is a member of the IFN-inducible transmem-
brane (IFITM) protein family that was originally identi-
fied as Leu-13, a leukocyte antigen that is a part of a
membrane complex involved in the transduction of anti-
proliferative and homotypic adhesion signals in lympho-
cytes [56,57]. IFITM1 is highly induced by type 1
interferons (IFNs α and β) and is most well-known for
its ability to restrict the replication of a number of envel-
oped and non-enveloped viruses [30]. More recently,
IFITM1 has also been implicated in tumorigenesis and
there is evidence that it can positively or negatively regu-
late cell proliferation depending on the tumor cell type
[25,27,31,32,40]. In particular, IFITM1 overexpression
has been shown to inhibit proliferation in hepatoma cells
[29] and its constitutive overexpression has been shown
to positively correlate with improved survival in chronic
myeloid leukemia patients [25]. In contrast, upregulation
of IFITM1 expression has been reported to play a critical
role in both the precancerous stage and carcinogenesis
in patients with gastric mucosa infected with Helicobac-
ter pylori and cervical cancer [33]. In addition, there is
evidence that IFITM1 overexpression induces tumor re-
sistance to natural killer (NK) cells in gastric tumor cells
and it facilitates migration and invasion of gastric cancer
cells [29]. More recently, investigators have reported that
overexpression of IFITM1 promotes head and neck
tumor invasion in the early stages of disease progressionby mediating the expression of molecules downstream,
including matrix metalloproteinases 12 and 13 [32].
Our data provide strong evidence that constitutive
overexpression of IFITM1 is driven by IFNα through ac-
tivation of the canonical signaling pathway and that
STAT1 and STAT2 play a critical role. In particular, we
found that p-STAT1 and p-STAT2 (Figure 3F) were con-
stitutively overexpressed in our resistant cells and that
knockdown of IFNα dramatically reduced their expres-
sion in the cells. Furthermore, we found that knockdown
of STAT1 and STAT2 dramatically reduced IFITM1 ex-
pression in the resistant cells. However, we should note
that knockdown of IFNα or neutralizing IFNAR1/2 did
not completely suppress IFITM1 expression in the re-
sistant cells, which suggests that IFITM1 constitutive
overexpression might be regulated by other mechanisms.
Indeed, recent studies suggest that IFITM1 expression is
regulated by the chromatin remodeling complexes (CRCs)
consisting of BRG (Brahma-related gene) and BAF (BRM-
associated factor), which work in concert with histone
modification enzymes such as cyclic AMP-responsive-
element binding protein (CREB)-binding protein and/or
p300 (CBP/p300) to bring about the regulation of IFITM1
and other IFNα-target genes [58,59]. The BAF complexes
are thought to prime the IFITM1 promoter by disrupting
the nucleosome that covers the ISRE which then leads to
constitutive expression of IFITM1, as demonstrated in our
working model in Figure 9. Future studies will be aimed at
determining how IFITM1 and other ISGs are regulated by
the BRG/BAF complex in the resistant cells.
Conclusions
In summary, overexpression of ISGs and their protein
products are emerging as important contributors to de-
velopment of clinical neoplasia and drug resistance in
many types of cancers. In our study, we demonstrated
that several ISGs including IFITM1, STAT1 and PLSCR1
and their encoded proteins are constitutively overex-
pressed in AI-resistant breast cancer cells and AI-
resistant tumors and that their overexpression provides
a survival advantage in the resistant cells. Furthermore,
we showed that targeting ISGs, especially IFITM1, sensi-
tized AI-resistant breast cancer cells to estrogen-induced
cell death and it blocked the ability of these cells to mi-
grate and invade. This finding has important clinical im-
plications for patients with AI-resistant breast cancer
because it suggests that altered interferon signaling
might play a role in tumor progression and possibly the
development of AI resistance. Future studies will need
to address how and why interferon response genes are
altered during resistance and whether an altered im-
mune response gene profile can predict which patient
will benefit from AI therapy and which patient will de-
velop resistance following treatment.
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Additional file 1: Figure S1. Overexpression of ISGs in AI-resistant
MCF-7:5C cells as compared to parental MCF-7 cells. Total RNA was
extracted from each cell line and mRNA expression of the ISGs shown
above was determined by real-time PCR using PUM1 as the internal
control. Primer sequences for the ISGs shown above are described
in materials and methods. Fold change was calculated using the
ΔΔCT method and is displayed as relative to MCF-7 cells (control).
Values are means of triplicate measurements ± SD from two independent
experiments.
Additional file 2: Figure S2. Activation of interferon signaling pathway
in parental MCF-7 and AI-resistant MCF-7:5C cells in response to INF-a.
(A) MCF-7 and (B) MCF-7:5C cells were incubated with IFN-α (1000 U/ml) for
the indicated time points. The cell extracts were examined by Western blotting
using anti-PLSCR1, anti-IFITM1, anti-STAT1, anti-STAT2 and anti-b-actin. The
protein levels were quantified using the ImageJ software (downloaded
from NIH website) and normalized as the ratio relate to β-actin.
*P <0.05 or **P <0.01 versus control.
Additional file 3: Figure S3. Activation of IFN signaling pathway in
parental MCF-7 and AI-resistant MCF-7:5C cells in response to IFN-α. MCF-7
and MCF-7:5C cells were treated with 100 U/mL IFN-α and harvested at the
indicated time points. mRNA expression of IFITM1, PLSCR1 and STAT1was
measured using RT-PCR and calculated using the ΔΔCT method relative to
PUM1. mRNA expression is given as fold change over control (time zero).
Values shown are means of triplicate measurements ± SD from three
independent experiments.
Additional file 4: Figure S4. IFITM1 knockdown increases cell death in
AI-resistant breast cancer cells. (A, top panel) MCF-7:5C cells were
transfected with control shRNA (shCon), IFITM1 shRNA (shIFITM1) for
24 hours and then treated with 1 nM E2 for an additional 72 hours.
Cell extracts were subject to Western blotting for the level of IFITM1 and
PARP protein (top panel). Membranes were also stripped and reprobed for
β-actin, which was used as a loading control. (A, bottom panel) shIFITM1
mRNA level in resistant MCF-7:5C cells was determined by real-time PCR
and normalized to PUM1. *P <0.05 versus shcontrol (shCon). (B) Cell
proliferation was measured in resistant MCF-7:5C cells by MTT assay.
All the illustrated data were performed in triplicate and are expressed as
mean values of three independent experiments. Standard deviations are
shown. *P <0.05 versus control; #P <0.05 versus E2 treatment. (C) MCF-7:5C
cells were transfected with shCon or shIFITM1 and after 24 hours were
exposed to E2 (1 nM) for an additional 72 hours. Cells were then stained
with annexin V-FITC and PI for detection of apoptosis as described
in Methods.
Additional file 5: Figure S5. Role of IFN-α in estradiol-induced cell
death in resistant MCF-7:5C cells. Cells were transfected with siIFNα or
siCon for 24 hours and then further treated with 1 nM estradiol (E2) for
an additional 96 hours. In parallel experiments, we also pre-treated
MCF-7:5C cells with 5 μg/mL α-IFNAR antibody (MAB1155) for 4 hours and
then treated with 1 nM estradiol for an additional 96 hours. At the 96 hour
time point cells were harvested and proliferation was determined by MTT
assay (top) and apoptosis was assessed by annexin V/PI staining (bottom).
Data shown are expressed as mean values of three independent
experiments.
Additional file 6: Figure S6. STAT1/STAT2 knockdown reduces IFITM1
expression in MCF-7:5C cells. Cells were transfected with sicontrol (siCon),
STAT1 siRNA (siSTAT1), STAT2 siRNA (siSTAT2), or siSTAT1 and siSTAT2 for
48 hours and cells were harvested and analyzed by Western blot to
assess STAT1, STAT2 and IFITM1 protein expression. Membranes were
stripped and reprobed for β-actin, which was used as a loading control.
Blots shown are representative of three separate experiments yielding
similar results.Abbreviations
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